FDA 483 - Devalingam Mahalingam, M.D., Ph.D. - October 18, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Devalingam Mahalingam, M.D., Ph.D. in Chicago, IL, a clinical investigator, revealed significant deficiencies in clinical trial conduct. Observations included a failure to properly investigate a serious adverse event involving an investigational drug overdose that led to a subject's death. Additionally, the inspection found multiple instances where short form informed consent documents lacked required witness signatures for non-English speaking subjects.
ID · 4ce1169e-341a-4f08-a2f4-c77c9be80c69